Skip to main content
. 2014 Oct 29;15(12):1635–1645. doi: 10.4161/15384047.2014.964087

Figure 6.

Figure 6.

Combination of fruquintinib with chemo drugs shows enhanced anti-tumor effect in PDX models. (A) Fruquintinib in combination with taxotere (docetaxel) in gastric cancer PDX model. (B) Fruquintinib in combination with oxaliplatin in colon cancer PDX model. Percentage (%) represented tumor growth inhibition (TGI) rate. Two-tailed t-test for fruquintinib treatment versus the control group: *, P < 0.05; **, P < 0.01. The combination vs. single agent: #, P < 0.05; ##, P < 0.01.